Mettrum™ is a Health Canada licensed producer of medical cannabis, committed to ongoing research, quality production, and superior client service. With decades of combined expertise in the agri-pharma, distribution and technology industries, Mettrum clients and physicians enjoy access to uniquely tailored products and services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

LIFESPIN LAUNCHES COMMERCIAL ACCESS TO ITS METABOLIC PROFILER SOFTWARE AND DATABASE FOR PHARMA AND BIOBANK SERVICES

Lifespin | September 16, 2022

news image

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced that it has launched a new commercial service that, for the first time, will provide the pharmaceutical and biobanking industry with access to Lifespin’s proprietary metabolic database, along with its advanced interpretive software to assist in various phases of drug research, development, and manufacturing. Immediate applications of Lifespin’s commercial services will include quality c...

Read More

Views and Analysis

HARROW LAUNCHES ILEVRO®, NEVANAC®, AND MAXIDEX® IN THE U.S.

Businesswire | May 05, 2023

news image

Harrow a leading U.S. eyecare pharmaceutical company, announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for ILEVRO® (nepafenac ophthalmic suspension) 0.3%, NEVANAC® (nepafenac ophthalmic suspension) 0.1%, and MAXIDEX® (dexamethasone ophthalmic suspension) 0.1%. These three FDA-approved ophthalmic medicines, which are now commercially available under the Harrow umbrella, were among the five products that Harrow purchased in January of 2023 an...

Read More

Business Insights, PHARMACY MARKET

CYTEL AND GSK ADVANCE CLINICAL TRIAL DESIGN WITH SOLARA

Cytel | February 09, 2023

news image

On February 7, 2023, Cytel Inc., a provider of statistical software and advanced analytics in the life sciences industry, announced that GSK, one of the world's top biopharmaceutical firms, signed a three-year strategic agreement to increase GSK’s deployment of the clinical strategy platform Solara (R). This agreement will contribute significantly to the future development of the Solara platform. The platform can help GSK effectively align on trial goals, traverse trial uncertain...

Read More

Pharmacy Market

ICON SELECTED BY BARDA TO CONDUCT ANTHRAX VACCINE CLINICAL TRIAL

ICON plc | October 07, 2022

news image

ICON plc. a world-leading healthcare intelligence and clinical research organisation, announces that it has been selected by the US Biomedical Advanced Research and Development Authority part of the Administration for Strategic Preparedness and Response in the Department of Health and Human Services to execute an anthrax vaccine clinical trial. BARDA is providing funding to the Government and Public Health Solutions team at ICON to develop and execute a clinical trial that will ev...

Read More
news image

Business Insights

LIFESPIN LAUNCHES COMMERCIAL ACCESS TO ITS METABOLIC PROFILER SOFTWARE AND DATABASE FOR PHARMA AND BIOBANK SERVICES

Lifespin | September 16, 2022

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced that it has launched a new commercial service that, for the first time, will provide the pharmaceutical and biobanking industry with access to Lifespin’s proprietary metabolic database, along with its advanced interpretive software to assist in various phases of drug research, development, and manufacturing. Immediate applications of Lifespin’s commercial services will include quality c...

Read More
news image

Views and Analysis

HARROW LAUNCHES ILEVRO®, NEVANAC®, AND MAXIDEX® IN THE U.S.

Businesswire | May 05, 2023

Harrow a leading U.S. eyecare pharmaceutical company, announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for ILEVRO® (nepafenac ophthalmic suspension) 0.3%, NEVANAC® (nepafenac ophthalmic suspension) 0.1%, and MAXIDEX® (dexamethasone ophthalmic suspension) 0.1%. These three FDA-approved ophthalmic medicines, which are now commercially available under the Harrow umbrella, were among the five products that Harrow purchased in January of 2023 an...

Read More
news image

Business Insights, PHARMACY MARKET

CYTEL AND GSK ADVANCE CLINICAL TRIAL DESIGN WITH SOLARA

Cytel | February 09, 2023

On February 7, 2023, Cytel Inc., a provider of statistical software and advanced analytics in the life sciences industry, announced that GSK, one of the world's top biopharmaceutical firms, signed a three-year strategic agreement to increase GSK’s deployment of the clinical strategy platform Solara (R). This agreement will contribute significantly to the future development of the Solara platform. The platform can help GSK effectively align on trial goals, traverse trial uncertain...

Read More
news image

Pharmacy Market

ICON SELECTED BY BARDA TO CONDUCT ANTHRAX VACCINE CLINICAL TRIAL

ICON plc | October 07, 2022

ICON plc. a world-leading healthcare intelligence and clinical research organisation, announces that it has been selected by the US Biomedical Advanced Research and Development Authority part of the Administration for Strategic Preparedness and Response in the Department of Health and Human Services to execute an anthrax vaccine clinical trial. BARDA is providing funding to the Government and Public Health Solutions team at ICON to develop and execute a clinical trial that will ev...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us